Business Description
Sarepta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US8036071004
Share Class Description:
SRPT: Ordinary SharesDescription
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.86 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 1.15 | |||||
| Debt-to-EBITDA | 7.47 | |||||
| Interest Coverage | 4.23 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.48 | |||||
| Beneish M-Score | -1.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 24.8 | |||||
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 30.8 | |||||
| 3-Year Book Growth Rate | -1.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 46.29 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.18 | |||||
| 9-Day RSI | 45.35 | |||||
| 14-Day RSI | 47.11 | |||||
| 6-1 Month Momentum % | -12.67 | |||||
| 12-1 Month Momentum % | 42.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.84 | |||||
| Quick Ratio | 3.03 | |||||
| Cash Ratio | 1.71 | |||||
| Days Inventory | 629.62 | |||||
| Days Sales Outstanding | 84.22 | |||||
| Days Payable | 180.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.7 | |||||
| Shareholder Yield % | 0.21 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.92 | |||||
| Operating Margin % | 4.94 | |||||
| Net Margin % | 7.43 | |||||
| FCF Margin % | -29.29 | |||||
| ROE % | 12.48 | |||||
| ROA % | 3.66 | |||||
| ROIC % | 4.93 | |||||
| ROC (Joel Greenblatt) % | 16.84 | |||||
| ROCE % | 5.49 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 78.9 | |||||
| Forward PE Ratio | 10.65 | |||||
| PE Ratio without NRI | 74.49 | |||||
| PEG Ratio | 24.03 | |||||
| PS Ratio | 7.45 | |||||
| PB Ratio | 9.5 | |||||
| Price-to-Tangible-Book | 9.72 | |||||
| EV-to-EBIT | 79.47 | |||||
| EV-to-Forward-EBIT | 7.21 | |||||
| EV-to-EBITDA | 63.06 | |||||
| EV-to-Forward-EBITDA | 7 | |||||
| EV-to-Revenue | 7.2 | |||||
| EV-to-Forward-Revenue | 3.73 | |||||
| EV-to-FCF | -24.57 | |||||
| Price-to-DCF (Earnings Based) | 6.46 | |||||
| Price-to-Median-PS-Value | 0.29 | |||||
| Price-to-Graham-Number | 5.67 | |||||
| Price-to-Net-Current-Asset-Value | 37.85 | |||||
| Earnings Yield (Greenblatt) % | 1.26 | |||||
| FCF Yield % | -4.14 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SRPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sarepta Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,640.348 | ||
| EPS (TTM) ($) | 1.54 | ||
| Beta | 0.84 | ||
| Volatility % | 38.83 | ||
| 14-Day RSI | 47.11 | ||
| 14-Day ATR ($) | 3.942188 | ||
| 20-Day SMA ($) | 124.811 | ||
| 12-1 Month Momentum % | 42.44 | ||
| 52-Week Range ($) | 91.3439 - 173.25 | ||
| Shares Outstanding (Mil) | 95.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sarepta Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sarepta Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sarepta Therapeutics Inc Frequently Asked Questions
What is Sarepta Therapeutics Inc(SRPT)'s stock price today?
The current price of SRPT is $121.50. The 52 week high of SRPT is $173.25 and 52 week low is $91.34.
When is next earnings date of Sarepta Therapeutics Inc(SRPT)?
The next earnings date of Sarepta Therapeutics Inc(SRPT) is 2025-02-28 Est..
Does Sarepta Therapeutics Inc(SRPT) pay dividends? If so, how much?
Sarepta Therapeutics Inc(SRPT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers